Home › Premature Birth › NCT06207071
Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
Early DHA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
Who can join
24 Hours – 72 Hours · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Gestational ages between 22 0/7 - 32 6/7 weeks gestation * \< 25th centile birthweight Exclusion Criteria: * Major congenital/chromosomal anomalies * Terminal illness in which decisions to withhold or limit support have been made
About the study
Growth-restricted very preterm infants (VPT) are born without adequate fat mass (FM) deposits and low docosahexaenoic acid (DHA) concentrations. They often experience further declines in DHA concentrations during the initial three weeks post-birth while advancing enteral feeds and receiving lipid supplementation predominantly through parenteral nutrition. These suboptimal enteral and parenteral nutrition practices significantly heighten the risk of faltering postnatal growth. One promising approach to mitigate these issues is enteral DHA supplementation. However, it remains unclear whether the early administration of DHA through enteral supplementation could lead to a more substantial increase in head growth without affecting FM accretion in growth-restricted VPT infants. To address this question, we propose a masked randomized clinical trial involving 152 VPT infants.
What is being tested
- DHA (dietary supplement)
Sponsor: University of Alabama at Birmingham · Participants: 152 · Started: May 20, 2024
Contact the study team
- Ariel A Salas, MD, MSPH · Phone: 205-934-4680
Official record on ClinicalTrials.gov — NCT06207071
Locations in the U.S.
| Alabama | University of Alabama at Birmingham, Birmingham |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.